Skip to main content
. 2019 Nov 1;105(3):890–897. doi: 10.1210/clinem/dgz163

Figure 4.

Figure 4.

Proportion of participants achieving bone mineral density increases of >3% at all 3 sites from baseline to 9 and 15 months.b BL, baseline; FN, femoral neck; HD, high-dose teriparatide (40 μg) plus denosumab; LS, lumbar spine; M, month; SD, standard-dose teriparatide (20 μg) plus denosumab; TH, total hip.

*P < .05.

**P < .01. b

Includes 55 participants who had areal bone mineral density determinations at all study visits (baseline, month 9, and month 15) and at all sites (total hip, femoral neck, and lumbar spine).